Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

Blizzy Jul. 17 at 3:29 PM

$BEAM should be double this price, let’s go!!!

0 · Reply

KnockoutTrades Jul. 17 at 2:13 PM

$BEAM

0 · Reply

WilliamNextLvl Jul. 17 at 2:05 PM

$BEAM - Cathie Wood loves this company.

0 · Reply

GSTX7 Jul. 16 at 2:32 AM

$BEAM Thought about selling this the last few sessions. But nah. I'm in this one for the long haul. $16 avg and I think I'm gonna avg up...

1 · Reply

mankind1 Jul. 15 at 7:30 PM

$BEAM I'm a bit surprised that this dropped as much as it did. Time to buy!

0 · Reply

justiceforb_85 Jul. 15 at 6:01 PM

$BEAM adding on this dip. They will do well in A1AT. Bonus would be superior data to $CRSP in beta thalassemia/SCD.

0 · Reply

Kelly12 Jul. 15 at 5:10 PM

$BEAM buy the dip?

0 · Reply

sellthetop Jul. 15 at 2:34 AM

$BEAM - $100 dollar stock within 2 years if you just HOLD

0 · Reply

mankind1 Jul. 14 at 1:42 PM

$BEAM luckily I sold! But I'm coming back!

1 · Reply

Blizzy Jul. 14 at 12:34 PM

$BEAM short squeeze 🚀…..⏳⏳⏳

0 · Reply

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 13, 2025, 7:00 AM EDT - 4 weeks ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 6 weeks ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 6 weeks ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 2 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 2 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 3 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 3 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 3 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 4 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 4 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 4 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 4 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 5 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 5 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 6 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 6 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 6 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 7 months ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 7 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 7 months ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 8 months ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 8 months ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 9 months ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 9 months ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 9 months ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 9 months ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Feb 27, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Feb 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Jan 2, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

Nov 30, 2023, 4:36 AM EST - 1 year ago

CRISPR Gene Editing: Beam Therapeutics

Nov 10, 2023, 4:50 PM EST - 1 year ago

Beam Therapeutics: Sale Of Rights To Verve's In-Vivo Candidates An Odd Decision

Nov 8, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

Nov 8, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Oct 31, 2023, 6:00 AM EDT - 1 year ago

Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease

Oct 25, 2023, 6:30 AM EDT - 1 year ago

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

Blizzy Jul. 17 at 3:29 PM

$BEAM should be double this price, let’s go!!!

0 · Reply

KnockoutTrades Jul. 17 at 2:13 PM

$BEAM

0 · Reply

WilliamNextLvl Jul. 17 at 2:05 PM

$BEAM - Cathie Wood loves this company.

0 · Reply

GSTX7 Jul. 16 at 2:32 AM

$BEAM Thought about selling this the last few sessions. But nah. I'm in this one for the long haul. $16 avg and I think I'm gonna avg up...

1 · Reply

mankind1 Jul. 15 at 7:30 PM

$BEAM I'm a bit surprised that this dropped as much as it did. Time to buy!

0 · Reply

justiceforb_85 Jul. 15 at 6:01 PM

$BEAM adding on this dip. They will do well in A1AT. Bonus would be superior data to $CRSP in beta thalassemia/SCD.

0 · Reply

Kelly12 Jul. 15 at 5:10 PM

$BEAM buy the dip?

0 · Reply

sellthetop Jul. 15 at 2:34 AM

$BEAM - $100 dollar stock within 2 years if you just HOLD

0 · Reply

mankind1 Jul. 14 at 1:42 PM

$BEAM luckily I sold! But I'm coming back!

1 · Reply

Blizzy Jul. 14 at 12:34 PM

$BEAM short squeeze 🚀…..⏳⏳⏳

0 · Reply

RocroBio Jul. 14 at 5:37 AM

$BEAM $CRSP $EDIT $NTLA $PRME

0 · Reply

WeeklyOptionsTrading Jul. 11 at 5:19 PM

$BEAM added more today. I now have a full position. Cathie Wood loves this stock, so do I.

0 · Reply

sellthetop Jul. 11 at 5:07 PM

$BEAM I can smell $30

0 · Reply

Kevinp413 Jul. 11 at 1:05 PM

$BEAM in just under 20 for a long hold

0 · Reply

_Gibbon_ Jul. 11 at 2:59 AM

Gl $AVXL apes, been a nice run up but can't risk this going to cash value. Selling here and buying $BEAM, same upside w/o all the risk!

4 · Reply

sellthetop Jul. 10 at 7:05 PM

$BEAM this stock is going to 100 Don't say you weren't warned.

0 · Reply

Blizzy Jul. 10 at 3:35 PM

$BEAM I’m stuck up @$40 but I think with telegraphed rare cuts and market rotation this has a chance to get to $50+ by EOY 🤞🏼🚀⏳⏱️

0 · Reply

WilliamNextLvl Jul. 10 at 2:42 PM

$BEAM this stock has good momentum

0 · Reply

TheDuder45 Jul. 10 at 1:46 PM

$BEAM why does this always dump at open?

0 · Reply

Acadia2001 Jul. 10 at 12:36 PM

$BEAM Hope it breaches $23 today (my average) ! Keep it or sell 🤔

1 · Reply

AdmiralTweezers Jul. 10 at 8:52 AM

$BEAM $CRSP $EDIT $NTLA this is very big — it means biotechs can invest and have their investments have an impact. This also gives them back some of prior year taxes…..

3 · Reply

Momabeat Jul. 10 at 3:20 AM

$BEAM it just keeps going….

0 · Reply

Market Cap	1.97B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.10%
Debt to Equity Ratio	0.00

Volume	1,182,407
Avg Vol	2,121,954
Day's Range	N/A - N/A
Shares Out	100.56M
Stochastic %K	30%
Beta	2.07
Analysts	Strong Sell
Price Target	$44.67